Nanocovax / Nanogen Biopharma - LARVOL DELTA

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (clinicaltrials.gov) - P3 | N=13006 | Completed | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (clinicaltrials.gov) - P3 | N=13000 | Active, not recruiting | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2022 ➔ Dec 2022 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. (PubMed, Lancet Reg Health West Pac) - P1/2 | "Up to day 90, Nanocovax was found to be safe, well tolerated, and induced robust immune responses. This work was funded by the Coalition for Epidemic Preparedness Innovations (CEPI), the Ministry of Science and Technology of Vietnam, and Nanogen Pharmaceutical Biotechnology JSC."

Clinical • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. (PubMed, Front Immunol) - "albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Vietnam har en lignende vax i fase 3 as we speak - Nanocovax." (@ToMockAKillBird)

Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 (clinicaltrials.gov) - P3; N=13000; Recruiting; Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers (clinicaltrials.gov) - P1/2; N=620; Recruiting; Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease